|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the 31 paired samples, NR2C2 was more highly expressed in the recurrent as compared to the primary tumor.
|
31223310 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling.
|
31302002 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Additionally, endothelial TAK1 deletion reduces tumor burden.
|
30695692 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors.
|
30576901 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer.
|
30979739 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Remarkably, lnc-UCA1 knockdown combined with uORF overepression and NR2C2 knockdown led to severe tumor suppression in vivo.
|
30518750 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As TAK1 is implicated in dual feedforward mechanisms to orchestrate the SASP development, pharmacologically targeting TAK1 deprives cancer cells of resistance acquired from treatment-damaged stromal cells in vitro and substantially promotes tumour regression in vivo.
|
29712904 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The calmodulin-eEF2K, TR4 and p53 pathways may be involved in the tumor development.
|
28986304 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Early studies have indicated that testicular nuclear receptor 4 (TR4) first cloned from testis is involved in the invasion and metastasis of several human tumors; however, little attention is paid to the function of TR4 in seminoma.
|
29197138 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Downstream of SHP1 and SYK-dependent counterregulation of MyD88 tyrosine phosphorylation, we have demonstrated that the scaffolding function of receptor interacting protein kinase 1 (RIPK1) and tumor growth factor-β activated kinase 1 (TAK1)-mediating signaling were required to spur inflammatory disease.
|
28410990 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The activity of these inhibitors, in combination with the most commonly used chemotherapeutic drugs, has been tested in preclinical studies, proving the efficacy of TAK1 inhibition in reducing tumor growth and survival following chemotherapy administration.
|
29145973 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TAK1, a crucial mediator that upregulates NF-κB activation in response to cellular genotoxic stress, is required for tumor cell viability and survival.
|
28430599 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, MEK-162 treatment reduced TR4 protein expression and blocked recruitment of TR4 to bind its consensus site on the POMC promoter (-854bp to -637bp), elucidating multiple mechanisms to control TR4 corticotroph tumor actions.
|
27708250 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accumulating evidence demonstrates that TAK1 plays a role in tumor initiation, progression, and metastasis as a tumor prompter or tumor suppressor.
|
24443058 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these results suggest TR4 may function as a tumor suppressor to prevent or delay prostate tumorigenesis via regulating ATM expression at the transcriptional level.
|
24583925 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mapping studies have described a minimally deleted area at 6q15, containing MAP3K7/TAK1, which was recently shown to have tumor suppressive properties.
|
23370768 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We report that its restored expression induces the death of genetically diverse melanoma lines and inhibits tumor growth through the activation of novel TAK1-dependent death pathways.
|
22898869 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The orthotopic xenograft studies in SCID mice showed that suppression of TAK1 signaling by dn-TAK1 reduces tumor growth and formation of lung metastases.
|
17828308 |
2008 |